Jia-Ming Tian, Yi-He Dong, Zi Li, Yong Zhou, Jun Huang
{"title":"Androgen-induced AR-BRD4 transcriptional regulatory complex promotes malignant proliferation of osteosarcoma cells.","authors":"Jia-Ming Tian, Yi-He Dong, Zi Li, Yong Zhou, Jun Huang","doi":"10.1038/s41420-025-02541-6","DOIUrl":null,"url":null,"abstract":"<p><p>Osteosarcoma (OS) is deemed as hormone-dependent neoplasm. Here we explored its latent mechanisms governing the interactions between specific molecules and hormones involved in OS progression. Through multiplex IHC analysis in TMA, bioinformatics analysis, and a series of in vitro and in vivo molecular assays, we identified BRD4 and sex steroid receptors were positively expressed in clinical OS tissues, simultaneously BRD4 and AR expression were elevated in the osteoblastic subtype, while ERβ predominated in the fibroblastic subtype. GEO database revealed a positive correlation between BRD4 and AR expression, while no correlation was found with ERβ expression. In vitro studies demonstrated that DHT stimulation resulted in a significant upregulation of AR and BRD4 protein expression, subsequently promoting the proliferation of OS cells. ChIP-sequencing and dual-luciferase reporter assays revealed that DHT treatment increased the distribution of BRD4 on chromatin and its overlap with AR, facilitating the formation of the AR-BRD4 transcriptional regulatory complex, which significantly increased transcription levels of AR target genes, such as PLCB4. Moreover, experiments conducted in nude mice indicated that BRD4 inhibitor, (+)-JQ1 decreased the expression of AR-related genes and inhibited OS cell growth in vivo. In conclusion, elevated expression of BRD4 in OS cells induced by androgens participates in AR-related transcriptional regulatory processes, facilitating the malignant progression of OS.</p>","PeriodicalId":9735,"journal":{"name":"Cell Death Discovery","volume":"11 1","pages":"272"},"PeriodicalIF":6.1000,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12152148/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell Death Discovery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41420-025-02541-6","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Osteosarcoma (OS) is deemed as hormone-dependent neoplasm. Here we explored its latent mechanisms governing the interactions between specific molecules and hormones involved in OS progression. Through multiplex IHC analysis in TMA, bioinformatics analysis, and a series of in vitro and in vivo molecular assays, we identified BRD4 and sex steroid receptors were positively expressed in clinical OS tissues, simultaneously BRD4 and AR expression were elevated in the osteoblastic subtype, while ERβ predominated in the fibroblastic subtype. GEO database revealed a positive correlation between BRD4 and AR expression, while no correlation was found with ERβ expression. In vitro studies demonstrated that DHT stimulation resulted in a significant upregulation of AR and BRD4 protein expression, subsequently promoting the proliferation of OS cells. ChIP-sequencing and dual-luciferase reporter assays revealed that DHT treatment increased the distribution of BRD4 on chromatin and its overlap with AR, facilitating the formation of the AR-BRD4 transcriptional regulatory complex, which significantly increased transcription levels of AR target genes, such as PLCB4. Moreover, experiments conducted in nude mice indicated that BRD4 inhibitor, (+)-JQ1 decreased the expression of AR-related genes and inhibited OS cell growth in vivo. In conclusion, elevated expression of BRD4 in OS cells induced by androgens participates in AR-related transcriptional regulatory processes, facilitating the malignant progression of OS.
期刊介绍:
Cell Death Discovery is a multidisciplinary, international, online-only, open access journal, dedicated to publishing research at the intersection of medicine with biochemistry, pharmacology, immunology, cell biology and cell death, provided it is scientifically sound. The unrestricted access to research findings in Cell Death Discovery will foster a dynamic and highly productive dialogue between basic scientists and clinicians, as well as researchers in industry with a focus on cancer, neurobiology and inflammation research. As an official journal of the Cell Death Differentiation Association (ADMC), Cell Death Discovery will build upon the success of Cell Death & Differentiation and Cell Death & Disease in publishing important peer-reviewed original research, timely reviews and editorial commentary.
Cell Death Discovery is committed to increasing the reproducibility of research. To this end, in conjunction with its sister journals Cell Death & Differentiation and Cell Death & Disease, Cell Death Discovery provides a unique forum for scientists as well as clinicians and members of the pharmaceutical and biotechnical industry. It is committed to the rapid publication of high quality original papers that relate to these subjects, together with topical, usually solicited, reviews, editorial correspondence and occasional commentaries on controversial and scientifically informative issues.